107 related articles for article (PubMed ID: 37715423)
1. Low Expression of A3C and PLP2 Indicating a Favorable Prognosis in Human Gliomas.
Jin JS; Tsai YL; Chang YC; Tsai WC
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):71-79. PubMed ID: 37715423
[TBL] [Abstract][Full Text] [Related]
2. Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas.
Chen YH; Hueng DY; Tsai WC
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373180
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma.
Feng Z; Zhou W; Wang J; Qi Q; Han M; Kong Y; Hu Y; Zhang Y; Chen A; Huang B; Chen A; Zhang D; Li W; Zhang Q; Bjerkvig R; Wang J; Thorsen F; Li X
J Cell Mol Med; 2020 Mar; 24(5):2847-2856. PubMed ID: 31778016
[TBL] [Abstract][Full Text] [Related]
5. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis.
Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q
Front Immunol; 2023; 14():1242972. PubMed ID: 37809064
[TBL] [Abstract][Full Text] [Related]
6. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma.
Bai H; Zhu Y; Xu P; Chen B
Biomed Res Int; 2020; 2020():4286101. PubMed ID: 32596309
[TBL] [Abstract][Full Text] [Related]
7. MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2.
Xiao W; Wang C; Chen K; Wang T; Xing J; Zhang X; Wang X
EBioMedicine; 2020 Jan; 51():102622. PubMed ID: 31901870
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
9. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
10. CD45RO
Zhou WJ; Zhang J; Xie F; Wu JN; Ye JF; Wang J; Wu K; Li MQ
Theranostics; 2021; 11(11):5330-5345. PubMed ID: 33859750
[No Abstract] [Full Text] [Related]
11. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
13. Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.
Ding Z; Jian S; Peng X; Liu Y; Wang J; Zheng L; Ou C; Wang Y; Zeng W; Zhou M
Medicine (Baltimore); 2015 Aug; 94(33):e1327. PubMed ID: 26287415
[TBL] [Abstract][Full Text] [Related]
14. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
[TBL] [Abstract][Full Text] [Related]
15. MiR-422a weakened breast cancer stem cells properties by targeting PLP2.
Zou Y; Chen Y; Yao S; Deng G; Liu D; Yuan X; Liu S; Rao J; Xiong H; Yuan X; Yu S; Zhu F; Wang Y; Xiong H
Cancer Biol Ther; 2018 May; 19(5):436-444. PubMed ID: 29509055
[TBL] [Abstract][Full Text] [Related]
16. The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis.
Li X; Luo Y; Liu L; Cui S; Chen W; Zeng A; Shi Y; Luo L
J Cell Physiol; 2020 Mar; 235(3):2937-2946. PubMed ID: 31535380
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
18. PLP2 Could Be a Prognostic Biomarker and Potential Treatment Target in Glioblastoma Multiforme.
Qiao H; Li H
Pharmgenomics Pers Med; 2023; 16():991-1009. PubMed ID: 37964785
[TBL] [Abstract][Full Text] [Related]
19. Low expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomas.
Ke HH; Hueng DY; Tsai WC
Chin J Physiol; 2019; 62(1):35-43. PubMed ID: 30942197
[TBL] [Abstract][Full Text] [Related]
20. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
